Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | RECQL | P46063 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260049 | 0.99 | CYP2D6 (0.95) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL3211290 | 0.88 | CYP2D6 (0.76) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL15092821 | 0.88 | CYP2D6 (0.76) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL4750190 | 0.86 | CYP2D6 (0.74) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL4746006 | 0.84 | CYP2D6 (0.71) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL15092656 | 0.84 | LMNA (0.97) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL22407654 | 0.84 | LMNA (0.97) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL4750163 | 0.82 | LMNA (1.00) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL4749239 | 0.82 | CYP2D6 (0.68) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 | |
| SCHEMBL9239160 | 0.81 | CYP2D6 (0.67) | CYP2D6CYP2C19CYP1A2RECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| EP-1844027-A1 | THIAZOLIDINONES FOR USE AS INHIBITORS OF POLO-LIKE KINASE (PLK) | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1824834-A1 | META-SUBSTITUTED THIAZOLIDINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006082107-A1 | THIAZOLIDINONES FOR USE AS INHIBITORS OF POLO-LIKE KINASE (PLK) | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006063806-A1 | META-SUBSTITUTED THIAZOLIDINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | PLK2, PDXK, PLK4 | CYP2D6 731/4885CYP2C19 1086/4885CYP1A2 1451/4885 |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | PLK2, PLK4, PLK3 | CYP2D6 832/4885CYP2C19 820/4885CYP1A2 1203/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | CYP2D6 273/4885CYP2C19 334/4885CYP1A2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.